Surveillance of Adverse Events Following Immunization (AEFI) of the RTS,S/AS01 Malaria Vaccine in Three Pilot Districts of the Littoral Region, Cameroon, 2024–2026: A Cross-Sectional Descriptive Study
This cross-sectional study of routine surveillance data from January 2024 to August 2026 in three pilot districts of Cameroon's Littoral Region found that the RTS,S/AS01 malaria vaccine has a favorable safety profile, with the majority of reported adverse events being non-serious and the observed increase in notifications in one district likely reflecting improved surveillance sensitivity rather than a safety signal.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Malaria remains one of the most persistent threats to public health in sub-Saharan Africa, claiming hundreds of thousands of lives each year, with young children bearing the heaviest burden. For decades, the fight against this disease relied on bed nets, insecticides, and medicine, but the landscape changed with the arrival of a vaccine designed specifically for children. This vaccine, known as RTS,S/AS01, works by training the immune system to recognize and fight the parasite that causes malaria. However, introducing any new medical product on such a large scale requires a careful watchfulness. Just as a new bridge must be tested under real traffic to ensure it holds up, a vaccine must be monitored in the real world to confirm it is safe for the millions of children who will receive it. This process involves tracking any unexpected health problems that occur after a shot is given, a practice called surveillance. The goal is not to assume the vaccine is the cause of every illness that follows, but to listen closely for any patterns that might suggest a problem, ensuring that the benefits of protection continue to outweigh any risks.
In January 2024, Cameroon became the first African nation to roll out this malaria vaccine as a standard part of its childhood immunization program, moving beyond small pilot tests to a full national introduction. To understand how this vaccine was performing in the real world, researchers in three coastal districts of the Littoral Region—Edea, Japoma, and Mbanga—spent nearly three years gathering data on every reported health issue that occurred after a child received a dose. They looked at records from January 2024 through August 2026, examining nearly 300 reported events. The vast majority of these, about 288 cases, were classified as non-serious, meaning they were minor health issues that did not require hospitalization or cause long-term harm. Only seven cases were considered serious, involving life-threatening conditions or hospitalization. This distribution suggests that the vaccine is behaving safely in the general population, with the overwhelming number of reported issues being minor and manageable.
The researchers noticed a curious pattern in the data, particularly in the Japoma district. In 2025, the number of non-serious reports in this area jumped significantly compared to previous years, accounting for more than half of all such reports across the three districts. While a sudden rise in reports might initially sound alarming, the researchers found no evidence that the vaccine itself had become more dangerous. Instead, the increase coincided with a massive rise in the number of doses given in that district, and the researchers suggest this likely reflects a more attentive and sensitive reporting system rather than a new safety problem. It is similar to a town that suddenly starts counting every single pothole on its roads; the number of reported potholes goes up not because the road has deteriorated, but because the people counting are doing a better job of looking for them. The serious cases, which are the most critical to watch, remained rare and scattered across different locations and times, showing no sign of clustering that would point to a specific batch of vaccine or a specific location causing harm.
Despite these reassuring findings, the study highlights a gap in the current system. The data collected came from routine health reports, which record that an event happened but often lack the detailed medical information needed to prove whether the vaccine actually caused the event. For the seven serious cases, the researchers could not determine if they were linked to the shot or if they were simply coincidental illnesses that happened to occur around the same time. The authors emphasize that while the safety profile looks favorable, the system needs to improve how it investigates these serious events. By strengthening the ability to assess the cause of each serious case and standardizing how health workers report them, officials can maintain public trust and ensure that the vaccine continues to be a safe and effective tool in the fight against malaria. The study concludes that the vaccine is performing well in these pilot districts, but the work of watching and learning must continue as the program expands to cover the entire country.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.